Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: EC:2.7.7.49 (reverse transcriptase)
 31,746 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

SPLUNC1, originally named PLUNC for palate, lung and nasal epithelium clone, is a small protein which is secreted from the epithelial cells of the nasal cavity and the upper respiratory tract in humans, mice, rats and cows. SPLUNC1 is structurally homologous to the two key mediators of host defense against Gram-negative bacteria, lipopolysaccharide binding protein (LBP) and bactericidal permeability increasing protein (BPI). SPLUNC1 is therefore believed to play a role in the innate immune system. This work reports the cloning and analysis of the porcine (Sus scrofa) homologue of SPLUNC1. The SPLUNC1 cDNA was amplified by reverse transcriptase polymerase chain reaction (RT-PCR) using oligonucleotide primers derived from in silico sequences. The porcine cDNA codes for a protein of 249 amino acids which shows a high similarity to bovine (74%) and to human (69%) SPLUNC1. The predicted S. scrofa SPLUNC1, SsSPLUNC1, polypeptide contains a putative signal peptide of 19 residues. A similar signal sequence is also found in all other members of the PLUNC family. Expression analysis by RT-PCR demonstrated a very high expression level of the porcine SPLUNC1 homologue in trachea and lung tissue only. This airway-specific expression might be of particular interest in the study of airborne diseases in pig.
 ...
PMID:Porcine SPLUNC1: molecular cloning, characterization and expression analysis. 1577 15

The expression of CK19, LUNX, and KS1/4 mRNA biomarkers was detected in the peripheral blood of non-small cell lung cancer (NSCLC) patients to investigate the feasibility of indicating lung cancer micrometastases. Micrometastases were identified in the peripheral blood of 32 NSCLC patients, 15 benign pulmonary disease (BPD) patients, and 10 healthy volunteers by reverse transcriptase-polymerase chain reaction. The detection rates of CK19, LUNX, and KS1/4 mRNA-positive cells in the peripheral blood obtained from the NSCLC group were 34.4% (11/32), 37.5% (12/32), and 25% (8/32), respectively. CK19, LUNX, and KS1/4 mRNA-positive cells were detected in 6.6% (1/15), 0.0% (0/15), and 13.3% (2/15) of the patients with BPD, respectively. However, the healthy group did not express any of the three markers. The expression of CK19, LUNX, and KS1/4 mRNA was significantly higher in the NSCLC group than that in the healthy and BPD groups (P < 0.05). CK19 and LUNX mRNA may be ideal biomarkers indicating micrometastases in patients with NSCLC; however, the diagnostic applicability of KS1/4 mRNA remains uncertain. The rate of expression of CK19 was not correlated with the clinicopathological characteristics (P > 0.05). The rate of expression of LUNX and KS1/4 was closely related to the clinical stage (P < 0.05), and not related to the clinical characteristics of the disease (age, gender, smoking history, pathological type, histologic classification, and differentiation; P > 0.05).
 ...
PMID:Detection of CK19, LUNX, and KS1/4 mRNA expression in the peripheral blood for diagnosis of micrometastases in patients with non-small cell lung cancer and their clinical implications. 2663 71